Survodutide is the dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim (BI 456906) that produced up to 18.7% weight loss in its 46-week Phase 2 trial. Unlike semaglutide (pure GLP-1) or tirzepatide (GLP-1 + GIP), survodutide adds glucagon agonism — which drives energy expenditure upward while GLP-1 suppresses appetite. Different mechanism, different fat-loss profile, different side-effect pattern.
This guide covers what you should actually pay per milligram, which vial size fits weekly titration, how to verify a COA for a 29-amino-acid peptide with a lipid modification, and the vendor red flags to avoid. Survodutide is still pre-approval, which means supply is concentrated among a handful of research peptide vendors — and quality varies.
This is not a ranked vendor list — for that, see our Best Survodutide Vendors comparison. This guide teaches you how to evaluate any vendor yourself.
Why Survodutide Is Worth Buying Carefully
Survodutide is a 29-amino-acid peptide that binds both the GLP-1 receptor and the glucagon receptor with roughly balanced potency. Its C18 fatty-diacid side chain extends half-life to ~7 days, enabling weekly subcutaneous dosing. The dual agonism creates a distinct mechanism profile:
- GLP-1 arm — appetite suppression, delayed gastric emptying, improved insulin response
- Glucagon arm — increased hepatic fat oxidation, higher resting energy expenditure, mobilization of liver triglycerides
That glucagon component is why survodutide performs especially well in patients with MASH (metabolic-associated steatohepatitis). The Phase 2 MASH trial showed 83% of participants achieved histological improvement at 48 weeks. For the weight-loss market, the practical read is: survodutide produces weight loss comparable to tirzepatide (~19% at peak dose) but with a different fat-loss distribution — more visceral and hepatic fat mobilization.
But here's the catch: glucagon agonism is also why tolerability is tighter. Side effects including nausea, vomiting, and transient blood glucose increases are more pronounced at peak dose than with pure GLP-1 agonists. This makes titration discipline critical, which in turn makes vial-size selection important for dose flexibility.
The peptide itself is chemically complex — same C18 fatty-diacid attachment chemistry as semaglutide. Cheap manufacturers skip the lipidation and sell the unmodified 29-amino-acid backbone. It weighs right on HPLC. It does not work on a weekly schedule.
Understanding Survodutide Pricing
Survodutide is sold as lyophilized powder in sealed glass vials. Three factors move price: vial size, lipid-conjugation quality control, and vendor investment in third-party COAs.
Current Market Pricing (2026)
| Vial Size | Typical Price Range | Price Per mg | Best For |
|---|---|---|---|
| 5 mg | $40-85 | $8-17/mg | Starter titration (0.6-1.2 mg/week) |
| 10 mg | $70-160 | $7-16/mg | Standard — best all-around |
| 15 mg | $100-220 | $6.67-14.67/mg | Mid-protocol value |
| 20 mg | $130-280 | $6.50-14/mg | Long protocols, requires aliquot planning |
The pattern is clear: 10mg is the sweet spot because it fits the 28-day reconstitution window at most doses (2-4.8 mg/week) and offers meaningfully better per-mg pricing than 5mg. Larger sizes save another 10-15% per mg but require reconstitution discipline.
Cost Per Week at Common Doses
| Weekly Dose | Vial Duration (10mg) | Monthly Cost (10mg vial) |
|---|---|---|
| 0.6 mg/week (starter) | 16 weeks | $4-10/month |
| 1.2 mg/week (titration) | 8 weeks | $9-20/month |
| 2.4 mg/week (mid) | 4 weeks | $18-40/month |
| 4.8 mg/week (Phase 2 max) | 2 weeks | $35-80/month |
For current vendor-specific pricing with exact $/mg breakdowns, see our Best Survodutide Vendors comparison.
What to Look For: COA, Purity, Storage
Survodutide is a 29-amino-acid peptide with a molecular weight of roughly 4,610 Da in its fully-lipidated form. The C18 fatty-diacid side chain is attached to lysine via a γ-Glu-ADO linker — the same general chemistry semaglutide uses. Without that chain, the peptide is ~4,200 Da and has a half-life closer to hours, not a week.
What a COA (Certificate of Analysis) Should Include
Identity Confirmation
- Mass spectrometry confirming the fully-lipidated molecular weight (~4,610 Da, not the ~4,200 Da backbone)
- Amino acid sequence verification including the lipidation site
Purity Testing
- HPLC purity — look for 98%+ purity
- Chromatogram should show a single dominant peak; watch for a secondary peak around 4,200 Da signaling unlipidated impurity
Contamination Testing
- Endotoxin levels (subcutaneous injection)
- Residual solvent analysis (acetonitrile, TFA)
- Heavy metals screening
How to Verify a COA Is Legitimate
-
Check the testing lab — Janoshik Analytical, MZ Biolabs, and Colmaric Analyticals are the standard. In-house testing for a lipidated peptide is a serious red flag.
-
Verify the mass — the lipidated form is ~4,610 Da. Anything significantly lower means the fatty-acid conjugation was skipped or incomplete.
-
Verify on the lab's website — Janoshik task numbers can be looked up at janoshik.com.
-
Check the date — COAs should be within 6 months. Because survodutide supply is still thin, some vendors reuse older COAs across new batches.
-
Match the batch — batch/lot number on the COA must match the vial.
